QIAGEN and NVIDIA Partner to Advance AI-Driven Drug Discovery With BioNeMo and Biomedical Knowledge Graphs

Can AI cut years from the drug discovery timeline? NVIDIA's BioNeMo platform is combining with 25 years of QIAGEN's curated biomedical knowledge to boost both the speed and accuracy of AI-driven drug discovery.

Bioinformatics leader QIAGEN (NYSE: QGEN) announced a collaboration with NVIDIA (NVDA) to build an AI-powered drug discovery platform. The partnership integrates NVIDIA's BioNeMo platform and accelerated computing with QIAGEN Digital Insights' curated biomedical knowledge bases. The companies made the announcement at the 2026 BIO-IT World Conference in Boston.

Graph-Based AI Redefines Drug Discovery

Drug discovery requires connecting vast amounts of biological information — genes, diseases, pathways, compounds, and clinical evidence. The challenge: finding the most relevant connections within exploding data volumes, and verifying that AI-generated hypotheses have real biological credibility.

QIAGEN and NVIDIA are addressing this with graph-based AI that applies retrieval and reasoning techniques over biomedical knowledge graphs. Using PyTorch Geometric and GPU-accelerated GraphRAG systems delivered through the NVIDIA BioNeMo platform, researchers can query the knowledge graph in natural language while maintaining direct links to structured scientific evidence.

QIAGEN's Knowledge Base: 25 Years of Curation

QIAGEN Digital Insights has spent more than 25 years building the biomedical knowledge foundation that researchers rely on to interpret complex biology. Through this collaboration with NVIDIA, we can accelerate the impact of that knowledge by combining it with advanced AI to help customers improve critical steps in drug discovery.

Nitin Sood, SVP and Head of Product Portfolio & Innovation, QIAGEN

QIAGEN Digital Insights' knowledge bases are used by more than 150,000 scientists worldwide and are supported by more than 70,000 scientific publications. The platform organizes evidence across genes, diseases, pathways, compounds, clinical insights and more than 30,000 diseases.

• Scale: Used by 150,000+ scientists, backed by 70,000+ scientific publications
• Coverage: 30,000+ diseases, integrating genes, pathways, compounds, and clinical insights
• Applications: Target ID, drug repurposing, biomarker discovery, pathway analysis, multi-omics hypothesis generation
• Tech stack: NVIDIA BioNeMo platform, PyTorch Geometric, GPU-accelerated GraphRAG

Full Drug Discovery Lifecycle: From Targets to Biomarkers

The collaboration is designed to support the full drug discovery lifecycle. AI can more rapidly identify disease mechanisms and promising therapeutic targets, find new indications for existing approved drugs, and support biomarker discovery that improves clinical trial success rates. Agentic multi-step workflows allow natural language queries across the full biomedical knowledge graph.

Initial pilot programs will be made available to select pharmaceutical and biotechnology partners, with broader availability expected following validation. The QIAGEN Discovery Platform is designed to support agentic, multi-step workflows where AI guides hypothesis generation with structured scientific evidence at every step.

Healthcare AI Investment Race Accelerates

NVIDIA is pursuing a strategy to establish BioNeMo as the standard AI computing platform for pharma and biotech. Following the AlphaFold2 revolution in protein structure prediction, AI is rapidly moving from research curiosity to practical drug discovery tooling.

QIAGEN, best known for PCR kits, genomics analysis, and bioinformatics software, is using the NVIDIA partnership to accelerate its pivot toward a data interpretation and AI platform business. As pharma companies push to reduce R&D costs and improve success rates, the AI-driven drug discovery platform market is expected to grow sharply over the coming years.